Cellectis

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.[1] It has offices in Paris, France, New York, New York and Raleigh, North Carolina.

Cellectis
Société Anonyme
Traded as
IndustryBiotechnology, genome engineering, oncology
Founded1999
FounderAndré Choulika 
Headquarters
  • Paris XIIIème (France)
Key people
André Choulika (CEO)
Products
Websitecellectis.com

History

Cellectis was founded by André Choulika in 1999.[2] It built up a successful business based on the use of meganucleases in genome engineering. Cellectis went public in 2007, and raised €21.2 million in a stock offering on EuroNext. In 2010 it acquired Cyto Pulse, which had developed a new electroporation technology,[3] and in 2011 it paid €28 million for Cellartis, a Swedish biotechnology company.[2] In January 2011 the company licensed TALEN gene-editing technology from Iowa State University and the University of Minnesota.[4][5]The company employed nearly 300 people in early 2014.[2]

With the advent of the CRISPR (clustered regularly interspaced short palindromic repeat) genome editing technique, the Cellectis meganuclease technology became uneconomic, and by 2013 the company was close to bankruptcy. It restructured, closed laboratories and reduced staff, and shifted research emphasis toward CAR-T technologies for cancer immunotherapy. Early in 2014 it reached a substantial financing deal with Servier, and later in the same year made a much larger agreement with Pfizer and Allogene.[2]

In March 2015 the company raised $228 million through a stock offering on NASDAQ. The shares fell by 15% in the first week of trading.[6]

Calyxt

Cellectis formed the subsidiary of Calyxt in 2010[7] to develop healthier food ingredients through gene editing.[8] Based in Roseville, Minnesota, the subsidiary filed for an IPO in June, 2017.[9]

CAR-T cancer treatment

Cellectis is developing “off-the-shelf” CAR T-cell treatments meant to work for any person who has certain types of blood cancer.[10]

Most CAR-T therapies under development as of 2017 involved taking T-cells from the person with cancer and applying gene therapy to those cells to activate them to attack the person's cancer; an autologous cell therapy approach. Cellectis' approach starts with T-cells taken from healthy donors (allogeneic or allograft) and modifying these base cells with gene editing to disable the gene that causes donor immune cells to attack their host (preventing graft vs host disease). The base cells can then be modified the same way other CAR-T therapeutics are.[11]

UCART123 is in phase 1 trials for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukaemia (AML).[12] In early September 2017, the FDA suspended Cellectis’ Phase I trials of UCART123 in the wake of the death of a BPDCN patient from cytokine release syndrome (CRS).[12] The FDA hold was lifted in November 2017 after reducing the dosage and with additional conditions.[13] Cellectis also has a phase 1 trial for UCART22 in B-cell acute lymphoblastic leukemia (B-ALL) and received an IND approval from the FDA on their UCARTCS1 product candidate in multiple myeloma.[14]

Manufacturing

To manufacture its product candidates, Cellectis recently started building two manufacturing facilities - one in Paris, France called SMART and one in Raleigh, North Carolina called IMPACT. [15]

References
  1. Bryce Elder, Arash Massoud, Andrew Ward, David Crow (28 May 2015). Biotech Cellectis in takeover talks with Pfizer. Financial Times. Accessed March 2016. (subscription required).
  2. Philip Hemme (15 July 2015). "How Servier saved Cellectis, the French CAR-T Miracle". Labiotech.eu. Retrieved 16 March 2016.
  3. "Genetic Engineering & Biotechnology News - Biotech from Bench to Business". Genengnews.com. 8 November 2013. Archived from the original on 22 March 2016. Retrieved 16 March 2016.
  4. Marx, V (November 2012). "Genome-editing tools storm ahead". Nature Methods. 9 (11): 1055–9. doi:10.1038/nmeth.2220. PMID 23132115.
  5. "Cellectis Nabs TAL Effector IP from Minnesota and Iowa State Universities". GEN. 20 January 2011.
  6. "US IPO Weekly Recap: SolarEdge shines while other IPOs fall flat". NASDAQ.com. 27 March 2015. Retrieved 18 September 2017.
  7. Rehkamp, Patrick (21 July 2017). "Biotech firm Calyxt goes public, shares climb 30 percent". www.bizjournals.com. Retrieved 8 October 2017.
  8. "The First Gene-Edited Food Is Now Being Served". Twin Cities Business. Retrieved 18 January 2018.
  9. "Agricultural biotechnology company Calyxt files for IPO". Star Tribune. Retrieved 26 October 2017.
  10. Weintraub, Karen. "Powerful Childhood Cancer Treatment Holds Promise--and Poses Hazards". Scientific American. Retrieved 8 October 2017.
  11. "Gene editing has saved the lives of two children with leukaemia". New Scientist. Retrieved 8 October 2017.
  12. McKee, Selina (5 September 2017). "FDA holds trials of Cellectis' cell therapy after patient death". www.pharmatimes.com. Retrieved 8 October 2017.
  13. FDA Lifts Clinical Hold on Cellectis’ UCART123 Phase 1 Trials in AML, BPDCN. nov 2017
  14. "Possible Multiple Myeloma CAR T-cell Therapy to Enter Phase 1 Trial, Cellectis Says". Myeloma Research News. 22 April 2019. Retrieved 11 July 2019.
  15. "Cellectis to bring CAR-T manufacturing in-house with new plants". BioPharma Dive. Retrieved 11 July 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.